Tanaka M, Kanamori H, Kuwabara H, Yamaji S, Kamijo A, Taguchi J, Fujita H, Fujisawa S, Matsuzaki M, Mohri H, Ishigatsubo Y
First Department of Internal Medicine, Yokohama City University School of Medicine.
Rinsho Ketsueki. 2001 Aug;42(8):656-8.
We report a patient with chronic myelogenous leukemia who received a second transplant from a one-locus HLA-mismatched unrelated donor after rejection of an initial bone marrow graft. For the first transplant, HLAs were fully matched, conditioning with busulfan + cyclophosphamide (CY) was applied, and cyclosporin A + short-term methotrexate (sMTX) was used for prophylaxis against GVHD. A complete chimera was not obtained, and the graft was rejected on day 122. For the second transplant, there was a one-HLA locus (DR) mismatch, conditioning was done with total body irradiation + cytarabine + CY, and GVHD prophylaxis consisted of FK506 + sMTX. Engraftment was obtained on day 27, and no graft failure was occurred at the time of writing. This case suggests that strong immunosuppression may have prevented rejection of the second bone marrow graft.
我们报告了一名慢性粒细胞白血病患者,该患者在初次骨髓移植被排斥后,接受了来自一位HLA单位点不匹配的无关供者的第二次移植。第一次移植时,HLA完全匹配,采用白消安+环磷酰胺(CY)进行预处理,并使用环孢素A+短期甲氨蝶呤(sMTX)预防移植物抗宿主病(GVHD)。未获得完全嵌合体,移植物在第122天被排斥。第二次移植时,存在一个HLA位点(DR)不匹配,采用全身照射+阿糖胞苷+CY进行预处理,GVHD预防采用FK506+sMTX。在第27天实现植入,在撰写本文时未发生移植物失败。该病例表明,强效免疫抑制可能预防了第二次骨髓移植的排斥反应。